{"id":"rosuvastatin-7-days","safety":{"commonSideEffects":[{"rate":"3-5","effect":"Myalgia (muscle pain)"},{"rate":"1-3","effect":"Elevated liver enzymes (ALT/AST)"},{"rate":"5-10","effect":"Headache"},{"rate":"<0.1","effect":"Rhabdomyolysis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rosuvastatin is a statin that competitively inhibits HMG-CoA reductase, which catalyzes the conversion of HMG-CoA to mevalonate in the cholesterol biosynthetic pathway. This inhibition decreases hepatic cholesterol production, leading to upregulation of LDL receptors on hepatocytes and increased clearance of LDL cholesterol from the bloodstream. The net result is a significant reduction in serum LDL cholesterol and triglycerides, with modest increases in HDL cholesterol.","oneSentence":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:06:09.177Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia"},{"name":"Primary and secondary prevention of cardiovascular disease"}]},"trialDetails":[{"nctId":"NCT07372625","phase":"PHASE1","title":"A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.","status":"RECRUITING","sponsor":"PMV Pharmaceuticals, Inc","startDate":"2026-02-04","conditions":"TP53 Y220C Mutation, Advanced Solid Tumors","enrollment":14},{"nctId":"NCT07088913","phase":"PHASE1","title":"A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-07-28","conditions":"Healthy Participants","enrollment":20},{"nctId":"NCT03016819","phase":"PHASE3","title":"Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)","status":"RECRUITING","sponsor":"Advenchen Laboratories, LLC","startDate":"2017-08-15","conditions":"Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma","enrollment":325},{"nctId":"NCT06981299","phase":"PHASE1","title":"A Phase 1 Study of PROT-001.","status":"COMPLETED","sponsor":"Protego Biopharma Pty Ltd","startDate":"2025-05-29","conditions":"Healthy","enrollment":102},{"nctId":"NCT04481789","phase":"PHASE1","title":"Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-10-17","conditions":"Healthy Adult Subjects","enrollment":84},{"nctId":"NCT07316608","phase":"PHASE1","title":"A Phase I, Open-label, Crossover Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-16","conditions":"Healthy Participants","enrollment":44},{"nctId":"NCT06948747","phase":"PHASE1","title":"A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-05-06","conditions":"Healthy Participants","enrollment":49},{"nctId":"NCT06071442","phase":"PHASE1","title":"Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-01-17","conditions":"Healthy Participants","enrollment":60},{"nctId":"NCT06335134","phase":"PHASE1","title":"A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin","status":"COMPLETED","sponsor":"Hangzhou Sciwind Biosciences Co., Ltd.","startDate":"2023-07-14","conditions":"Healthy Volunteers","enrollment":57},{"nctId":"NCT06877390","phase":"NA","title":"Effect of Enhanced External Counterpulsation","status":"COMPLETED","sponsor":"Chongming Hospital Affiliated to Shanghai University of Health & Medicine Sciences","startDate":"2023-11-01","conditions":"Enhanced External Counterpulsation (EECP), Acute Myocardial Infarction (AMI), Drug-coated Balloon","enrollment":60},{"nctId":"NCT04656028","phase":"NA","title":"Genetic Testing and Motivational Counseling for FH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Therapy and Preventive Medicine","startDate":"2020-06-15","conditions":"Hypercholesterolemia, Familial, Hypercholesterolemia, Familial, 1, Hypercholesterolemia, Familial, 2","enrollment":180},{"nctId":"NCT05926180","phase":"PHASE1","title":"Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)","status":"COMPLETED","sponsor":"Dizal Pharmaceuticals","startDate":"2023-07-31","conditions":"Non-small Cell Lung Cancer","enrollment":25},{"nctId":"NCT05657613","phase":"PHASE1","title":"Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2023-01-03","conditions":"Drug Interactions","enrollment":60},{"nctId":"NCT03864042","phase":"PHASE1","title":"Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-01-02","conditions":"Advanced Solid Tumors, Metastatic Melanoma","enrollment":56},{"nctId":"NCT05176314","phase":"PHASE1","title":"A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants","status":"COMPLETED","sponsor":"Loxo Oncology, Inc.","startDate":"2022-01-11","conditions":"Healthy","enrollment":32},{"nctId":"NCT06247748","phase":"PHASE1","title":"Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects","status":"COMPLETED","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2023-10-19","conditions":"Diabetes Mellitus, Type 2, Overweight","enrollment":28},{"nctId":"NCT06348290","phase":"PHASE1","title":"Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Jemincare","startDate":"2024-04-01","conditions":"Solid Tumor, Adult","enrollment":72},{"nctId":"NCT06092931","phase":"PHASE1","title":"A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants","status":"COMPLETED","sponsor":"DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company","startDate":"2023-10-16","conditions":"Healthy Participants","enrollment":28},{"nctId":"NCT04931147","phase":"PHASE1","title":"A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers","status":"COMPLETED","sponsor":"Redx Pharma Ltd","startDate":"2021-05-13","conditions":"Fibrosis, Inflammation, Idiopathic Pulmonary Fibrosis","enrollment":90},{"nctId":"NCT05708573","phase":"PHASE1","title":"Potential Drug Interaction Between ALXN2040 and Rosuvastatin","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2023-02-01","conditions":"Healthy Participants","enrollment":20},{"nctId":"NCT05658692","phase":"PHASE4","title":"Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-10-01","conditions":"Acute Respiratory Distress Syndrome","enrollment":1000},{"nctId":"NCT05480475","phase":"PHASE1","title":"A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Dabigatran and Rosuvastatin in Healthy Male Subjects","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2022-09-03","conditions":"Healthy","enrollment":24},{"nctId":"NCT04428086","phase":"PHASE1","title":"A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects.","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-07-27","conditions":"Solid Tumor, Adult","enrollment":19},{"nctId":"NCT03889314","phase":"PHASE4","title":"The DEtermining Statin Intolerance FOr Rosuvastatin (DESIFOR) Trial","status":"UNKNOWN","sponsor":"Minneapolis Heart Institute Foundation","startDate":"2019-04-26","conditions":"Cardiovascular Risk Factor, Cardiovascular Diseases, Adverse Effect","enrollment":25},{"nctId":"NCT00885495","phase":"PHASE1, PHASE2","title":"Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2009-01","conditions":"HIV Infections","enrollment":17},{"nctId":"NCT01953835","phase":"PHASE1","title":"A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10-04","conditions":"Systemic Lupus Erythematosus","enrollment":37},{"nctId":"NCT04231435","phase":"PHASE1","title":"Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin","status":"COMPLETED","sponsor":"Celgene","startDate":"2019-12-18","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT04092595","phase":"PHASE1","title":"A Study of PF-06651600 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-09-26","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT03526367","phase":"PHASE4","title":"A Randomized Trial of Rosuvastatin Loading Combined With Early hydrAtion Versus Standard-of-care Medications for the Prevention of CIAKI in Patient With AMI Undergoing Emergency PCI","status":"WITHDRAWN","sponsor":"Shenyang Northern Hospital","startDate":"2019-02-20","conditions":"Contrast-induced Acute Kidney Injury, ST Elevation Myocardial Infarction, Primary PCI","enrollment":""},{"nctId":"NCT02704702","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male Subjects","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2016-03","conditions":"Hypertension","enrollment":36},{"nctId":"NCT03339752","phase":"PHASE1","title":"A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-541468 Can Affect the Fate in the Body (Amount and Time of Presence in the Blood) of Rosuvastatin","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2017-10-30","conditions":"Healthy Subjects","enrollment":20},{"nctId":"NCT01153334","phase":"PHASE4","title":"Efficacy of Early Intensive ROsuvastatin Therapy in Patients With ST-segment Elevation Myocardial Infarction Undergoing PrimARY Percutaneous Coronary Intervention (the ROSEMARY Trial)","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-08-02","conditions":"ST-segment Elevation AMI","enrollment":125},{"nctId":"NCT02371603","phase":"PHASE1","title":"Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-02-11","conditions":"Anaemia","enrollment":70},{"nctId":"NCT03136237","phase":"PHASE1","title":"A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2017-02-17","conditions":"Hereditary Angioedema","enrollment":54},{"nctId":"NCT01411111","phase":"PHASE1","title":"A Repeat Dose Study to Investigate the Interaction of GSK2190915 on the Pharmacokinetics of Rosuvastatin","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-06","conditions":"Asthma","enrollment":28},{"nctId":"NCT02502110","phase":"PHASE4","title":"Study of Statin for Reduction of Postoperative Paroxysmal Atrial Fibrillation","status":"UNKNOWN","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2015-08","conditions":"Paroxysmal Atrial Fibrillation","enrollment":346},{"nctId":"NCT02300363","phase":"PHASE1","title":"DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2014-10","conditions":"Healthy","enrollment":24},{"nctId":"NCT01870466","phase":"PHASE1","title":"Pharmacodynamic Drug Interaction Between Cilostazol and Statins","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2012-06","conditions":"Healthy","enrollment":63},{"nctId":"NCT02089061","phase":"PHASE1","title":"Drug Interaction Statin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-03","conditions":"Acute Coronary Syndromes","enrollment":26},{"nctId":"NCT01955759","phase":"EARLY_PHASE1","title":"Atrial Fibrillation and By-pass Surgery","status":"UNKNOWN","sponsor":"Heart Center BH Tuzla","startDate":"2013-12","conditions":"Patients With Coronary Artery Disease Scheduled for by Pass Surgery","enrollment":260},{"nctId":"NCT01921946","phase":"PHASE1","title":"To Evaluate the Pharmacokinetic Interactions and Safety Between Fimasartan and Rosuvastatin","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2013-08","conditions":"Hypertension","enrollment":50},{"nctId":"NCT01823133","phase":"PHASE1","title":"Study for Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Rosuvastatin","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2013-04","conditions":"Healthy","enrollment":30},{"nctId":"NCT01918709","phase":"PHASE1","title":"Drug Interaction and Safety Between Valsartan and Rosuvastatin in Healthy Male Volunteers","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2011-09","conditions":"Hypertension, Hyperlipidemia","enrollment":30},{"nctId":"NCT01831479","phase":"PHASE1","title":"Investigation of Pharmacokinetic Interaction Between Rosuvastatin and Olmesartan in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Severance Hospital","startDate":"2011-08","conditions":"Healthy","enrollment":36},{"nctId":"NCT01823900","phase":"PHASE1","title":"Safety and Pharmacokinetic Comparison of Co-administration and a Combination Drug of Rosuvastatin and Olmesartan in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Severance Hospital","startDate":"2012-01","conditions":"Healthy","enrollment":58},{"nctId":"NCT01288742","phase":"PHASE1","title":"TMC435-TiDP16-C108 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Digoxin and Between TMC435 and Rosuvastatin","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2011-01","conditions":"Hepatitis C Virus","enrollment":33},{"nctId":"NCT01021488","phase":"PHASE4","title":"Rosuvastatin for Preventing Deep Vein Thrombosis","status":"UNKNOWN","sponsor":"Hallym University Medical Center","startDate":"2009-10","conditions":"Deep Vein Thrombosis, Venous, Thrombosis","enrollment":180},{"nctId":"NCT01138072","phase":"PHASE1","title":"A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06","conditions":"Infection, Human Immunodeficiency Virus","enrollment":14},{"nctId":"NCT00987974","phase":"PHASE4","title":"Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2009-09","conditions":"Ischemia Reperfusion Injury, Endothelial Dysfunction","enrollment":48},{"nctId":"NCT00851175","phase":"PHASE4","title":"Is Augmentation of PORH by Rosuvastatin Adenosine-receptor Mediated?","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2009-03","conditions":"Atherosclerosis, Cardiovascular Disease","enrollment":8},{"nctId":"NCT00554138","phase":"NA","title":"The Effect of Rosuvastatin on Adenosine Metabolism","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2007-11","conditions":"Adenosine Metabolism","enrollment":24},{"nctId":"NCT00457652","phase":"PHASE4","title":"Does Caffeine Reduce Rosuvastatin-Induced Protection Against Ischemia-Reperfusion Injury?","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2007-06","conditions":"Ischemia Reperfusion Injury","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["crestor"],"phase":"marketed","status":"active","brandName":"rosuvastatin 7 days","genericName":"rosuvastatin 7 days","companyName":"Radboud University Medical Center","companyId":"radboud-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia, Primary and secondary prevention of cardiovascular disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}